Willibald Hochholzer1, Christian T Ruff2, Robert A Mesa2, John F Mattimore2, John F Cyr2, Lanyu Lei3, Andrew L Frelinger4, Alan D Michelson4, David D Berg2, Dominick J Angiolillo5, Michelle L O'Donoghue2, Marc S Sabatine2, Jessica L Mega6. 1. Universitaets Herzzentrum Freiburg, Klinik für Kardiologie und Angiologie II, Bad Krozingen, Germany. 2. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 3. Harvard Clinical Research Institute, Boston, Massachusetts. 4. Center for Platelet Research Studies, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 5. University of Florida College of Medicine-Jacksonville, Jacksonville, Florida. 6. TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: jmega@partners.org.
Abstract
BACKGROUND: The degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneficial. OBJECTIVES: The aim of the study was to test the stability of platelet reactivity measurements over time among patients treated with standard and double doses ofclopidogrel. METHODS: The ELEVATE-TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various clopidogrel regimens. Patients with at least 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were analyzed. Platelet aggregation was measured using P2Y12 reaction units (PRU). RESULTS: In total, the mean platelet reactivity and the total number of nonresponders (PRU ≥230) with clopidogrel did not change between 2 periods for the 75-mg (22.4% vs. 21.9%; p = 0.86) and 150-mg doses of clopidogrel (11.5% vs. 11.5%; p = 1.00). In contrast, when evaluating each patient individually, 15.7% of patients taking clopidogrel 75 mg and 11.4% of patients taking 150 mg had a change in their responder status when tested at 2 different time points (p < 0.001). Despite being treated with the same dose of clopidogrel, >40% of patients had a change in PRU >40 on serial sampling, which approximates the average PRU difference caused by increasing the clopidogrel dose from 75 mg to 150 mg. CONCLUSIONS: Measurements of platelet reactivity vary over time in a significant proportion of patients. Thus, treatment adjustment according to platelet function testing at a single time point might not be sufficient for guiding antiplatelet therapy in clinical or research settings. (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56 [ELEVATE-TIMI 56]; NCT01235351).
RCT Entities:
BACKGROUND: The degree of antiplatelet response to clopidogrel has been associated with clinical outcomes. Studies have investigated whether adjustment of antiplatelet therapies based on a single platelet function test is beneficial. OBJECTIVES: The aim of the study was to test the stability of platelet reactivity measurements over time among patients treated with standard and double doses of clopidogrel. METHODS: The ELEVATE-TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various clopidogrel regimens. Patients with at least 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were analyzed. Platelet aggregation was measured using P2Y12 reaction units (PRU). RESULTS: In total, the mean platelet reactivity and the total number of nonresponders (PRU ≥230) with clopidogrel did not change between 2 periods for the 75-mg (22.4% vs. 21.9%; p = 0.86) and 150-mg doses of clopidogrel (11.5% vs. 11.5%; p = 1.00). In contrast, when evaluating each patient individually, 15.7% of patients taking clopidogrel 75 mg and 11.4% of patients taking 150 mg had a change in their responder status when tested at 2 different time points (p < 0.001). Despite being treated with the same dose of clopidogrel, >40% of patients had a change in PRU >40 on serial sampling, which approximates the average PRU difference caused by increasing the clopidogrel dose from 75 mg to 150 mg. CONCLUSIONS: Measurements of platelet reactivity vary over time in a significant proportion of patients. Thus, treatment adjustment according to platelet function testing at a single time point might not be sufficient for guiding antiplatelet therapy in clinical or research settings. (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56 [ELEVATE-TIMI 56]; NCT01235351).
Authors: Andrew Yang; Quin Pon; Andrea Lavoie; Jennifer J Crawford; Sebastian Harenberg; Rodney H Zimmermann; Jeff Booker; Sheila Kelly; Shahar Lavi; Warren J Cantor; Shamir R Mehta; Akshay Bagai; Shaun G Goodman; Asim N Cheema; Payam Dehghani Journal: J Thromb Thrombolysis Date: 2018-02 Impact factor: 2.300
Authors: S A Scott; J-P Collet; U Baber; Y Yang; I Peter; M Linderman; J Sload; W Qiao; A S Kini; S K Sharma; R J Desnick; V Fuster; R J Hajjar; G Montalescot; J-S Hulot Journal: Clin Pharmacol Ther Date: 2016-06-20 Impact factor: 6.875
Authors: Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2021-02-04 Impact factor: 1.764
Authors: Arwa M Amin; Lim Sheau Chin; Dzul Azri Mohamed Noor; Muhamad Ali Sk Abdul Kader; Yuen Kah Hay; Baharudin Ibrahim Journal: Cardiol Res Pract Date: 2017-03-21 Impact factor: 1.866
Authors: Sven Van Poucke; Dana Huskens; Kurt Van der Speeten; Mark Roest; Bart Lauwereins; Ming-Hua Zheng; Seppe Dehaene; Joris Penders; Abraham Marcus; Marcus Lancé Journal: PLoS One Date: 2018-06-21 Impact factor: 3.240